Skip to main content
OpenTrials
Completed

NCT Number: NCT03989609

Dexmedetomidine in Modifying Immune Paralysis In Patient With Septic Shock

in this study the investigators aim to assess the role of using dexmedetomidine as sedative in septic shock patients in comparison with midazolam. The investigators aim to assess the effect on immune response and inflammatory mediators and effect on vasopressors.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Kasr Alainy Hospital , Faculty of Medicine

Cairo, Egypt

About this study

Sedation protocol All patients will receive analgesia with fentanyl at fixed dose of 0.5 µg.kg.hr-1. Each patient will receive the study drug within 6 hours after ICU admission. Depth of sedation will be assessed using Richmond Agitation and Sedation Scale (RASS) scores (6), which range from -5 (unarousable) to +4 (combative). Study treatments will be infused without loading dose. Group I patients will have dexmedetomidine (4 µg.mL-1) and group II patients will have midazolam (0.33 mg.mL-1). Both drugs will be prepared in 0.9% sodium chloride in 50-mL syringe. Both the agents will be titrated to maintain the RASS in a range of -3 to -1. Dexmedetomidine infusion will be started at 0.1 µg.kg-1.hr-1 and will be adjusted by 0.1 µg.kg-1.h-1 to a maximum of 0.5 µg/kg/h, while midazolam will be started at 1 mg.h-1 (3 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (15 mL.h-1). All infusions will be adjusted by increments of 3 mL/hr-1. Patients in either group not adequately sedated by study drug titration will receive a bolus dose of fentanyl 0.5-1 µg.kg. Assessment of RASS score will be performed every 2 hours and prior to any dose of rescue therapy. The study drugs will be infused for 24 hours and after that the choice of sedation will be determined according to preference of attending physician.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age more than 18 years old
  • All mechanically ventilated patients who will be clinically suspected of having septic shock defined by infusion of at least one vasopressor and lactate > 2.0 mmol/l (5)

Exclusion criteria

  • Age < 18 years old
  • Pregnant patient
  • Source of sepsis not controlled
  • Acute hepatitis or severe liver disease (Child-Pugh class C)
  • Left ventricular ejection fraction less than 30%
  • Heart rate less than 50 beats/min
  • Second or third degree heart block
  • Systolic pressure < 90 mmHg despite of infusion of 2 vasopressors.
  • Psychological illness or severe cognitive dysfunction
  • Patients who are allergic to dexmedetomidine

Treatment and study plan

Dexmedetomidine Injection [Precedex]

Drug

Dexmedetomidine infusion will be started at 0.1 µg.kg-1.hr-1 and will be adjusted by 0.1 µg.kg-1.h-1 to a maximum of 0.5 µg/kg/h,

midazolam

Drug

midazolam will be started at 1 mg.h-1 (3 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (15 mL.h-1).

Primary outcomes

  1. Change in CD42/CD14

    Time frame: 24 hours after start of study drugs infusion

    Expression of CD42/CD14 will be measured by flow cytometry

Secondary outcomes

  1. effect on HLA-DR/CD14

    Time frame: Baseline before start of drug then 6, 12 and 24 hour after drug

    Expression of HLA-DR/CD14 will be measured by flow cytometry

  2. TNFα

    Time frame: Baseline before start of drug then 6, 12 and 24 hour after drug

    Expression of tumor necrosis factor (TNFα) will be measured by flow cytometry

  3. IL10

    Time frame: Baseline before start of drug then 6, 12 and 24 hour after drug

    Interleukin 10 will be measured by flow cytometry

  4. KIM-1 level

    Time frame: Baseline before start of drug and 24 hour after drug

    kidney injury molecule 1

  5. number of participants that will die within 28 days

    Time frame: within 28 dyas

    mortality within 28 days

Sponsors and collaborators

Lead sponsor

Kasr El Aini Hospital

Other

Registry information

Official study title

ROle of Dexmedetomidine in Modifying Immune Paralysis In Patient With Septic Shock: Randomized Controlled Trial (RODIS Trial)

Acronym: RODIS

Important dates

Study start
2019
Primary completion
2020
Study completion
2021
First posted
Jun 18, 2019
Registry last updated
Jul 19, 2022

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.